Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classifying antiarrhythmic actions: by facts or speculation.

E M Vaughan Williams1

  • 1Hertford College, Oxford, United Kingdom.

Journal of Clinical Pharmacology
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urea excretion by rabbits.

The Journal of physiology·2010
Same author

The relevance of cellular to clinical electrophysiology in classifying antiarrhythmic actions.

Journal of cardiovascular pharmacology·1992
Same author

Classification of the antiarrhythmic action of moricizine.

Journal of clinical pharmacology·1991
Same author

Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.

Journal of clinical pharmacology·1991
Same author

Relevance of cellular to clinical electrophysiology in interpreting antiarrhythmic drug action.

The American journal of cardiology·1989
Same author

Antiarrhythmic action of specific bradycardic agents.

European heart journal·1987
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
Same journal

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026
See all related articles

The Cardiac Arrhythmia Suppression Trials (CAST) support existing antiarrhythmic drug classifications. Classifying drug effects on cardiac tissue offers a rational basis for selecting arrhythmia treatments.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • The Cardiac Arrhythmia Suppression Trials (CAST 1 and 2) provided critical data on antiarrhythmic drug efficacy.
  • Existing antiarrhythmic classifications have faced recent criticism, notably
  • The Sicilian Gambit
  • proposal.

Purpose of the Study:

  • To review antiarrhythmic action classifications in light of CAST trial results.
  • To critically evaluate criticisms of existing classifications and discuss an alternative.
  • To validate the predictive power of drug classification for therapeutic selection.

Main Methods:

  • Review of CAST trial outcomes.
  • Detailed discussion of criticisms against the established antiarrhythmic classification.

Related Experiment Videos

  • Analysis of an alternative classification system.
  • Case study of cibenzoline's antiarrhythmic effects and classification predictions.

    • Main Results:

    • The CAST trials largely support the existing classification of antiarrhythmic actions.
    • An alternative classification, when refined, shows significant overlap with the original.
    • Predictions made based on cibenzoline's 1980 classification were confirmed by subsequent research and clinical trials.
    • Classification based on actual drug effects on cardiac tissue aligns with diagnostic-based treatment selection.

    Conclusions:

    • The current classification of antiarrhythmic drug actions remains a valid and useful tool.
    • Classifying antiarrhythmic drugs based on their effects on cardiac tissue provides a rational foundation for clinical decision-making.
    • Accurate classification aids in selecting the most appropriate therapy for specific cardiac arrhythmias.